Suzetrigine selectively inhibits the NaV1.8 pain-signaling pathway in the peripheral nervous system and provides effective ...
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.
Senate Judiciary Chairman Chuck Grassley of Iowa announced on Friday the introduction of a bill aimed at preventing opioid ...
In celebration of the major reduction in daily opioid prescriptions in Utah, leaders from the Utah Department of Health and ...
The company announced that the Food and Drug Administration (FDA) has approved Journavx, a twice-daily pill that it described as a "highly selective NaV1.8 pain signal inhibitor for the treatment of ...
Vertex Pharmaceuticals won approval from the U.S. Food and Drug Administration for a non-opioid pain drug, clearing the way for the rollout of a product that has simultaneously sparked high hopes and ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Too much news to include below, ...
The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.
It was given to people who had acute surgical pain from either abdominoplasty, also known as a tummy tuck, or bunion surgery.